

# Global Pharma Summit

## August 10-12, 2015 Philadelphia, USA

### Nanoparticles targeted drug delivery for Alzheimer's disease

**Adit Sharan**  
MicroLabs, India

The nature has very efficiently protected the human brain due to being one of the most delicate organs. The brain is protected by the blood brain barrier (BBB) and the blood cerebrospinal fluid barrier. Unfortunately, these protection mechanisms frustrate the therapeutic interventions by not allowing the drugs to enter the brain which in turn results in failure of a lot of active pharmaceutical agents in treating various brain disorders like Alzheimer's disease and many more. Alzheimer's disease represents the most common form of dementia worldwide, claimed to affect more than 35 million people. AD is the neurodegenerative progressive and irreversible disorder reported to affect 5% of Americans over age 65 and 20% over age 80. Considering the severity of the disease, pharmaceutical scientists are trying hard to overcome the brain barriers to get the required amount of drug delivered at the required site of action. Giving a hope, nanoparticles have shown a great promise in various such disorders. So the present monograph attempts to review the CNS barriers in context to Alzheimer's disease and various brain-targeted drug delivery systems (novel colloidal carriers especially) along with their rational attempts not only to deliver but also to target drugs to their site of action.

### Biography

Adit Sharan had done Bachelor in Pharmaceutical Sciences from Rayat-Bahra Institute of Pharmacy, Hoshiarpur, with affiliation to Punjab Technical University (Jalandhar). He have already attended and presented several papers in pharma seminars and conferences conducted nationally. He is currently with Micro Labs Ltd., since November 2012.

[adit.sharan@yahoo.com](mailto:adit.sharan@yahoo.com)